EXG202 / Exegenesis Bio - LARVOL DELTA

Efficient Retinal Transduction and Excellent Inhibitory Effect on Retinal Detachment of EXG202 delivered by intravitreal injection in NHP and a Severe Neovascularization and vascular leakage Mouse Model (ESGCT 2024) - "Four weeks post injection, the mice were given doxycycline to turn on expression of VEGF in photoreceptors. More importantly, reduction of total retinal detachment by 75% to 100% was observed in the Tet/opsin/VEGF double transgenic mice with doses of 1 × 108, 3 × 108, and 1 × 109 vg of EXG202. Taken together, data from this study strongly support clinical development of EXG202 in patients with nAMD or DME."

Preclinical • Anesthesia • Gene Therapies • Retinal Disorders

EXG202, a Novel Intravitreal Gene Therapy for Ocular Neovascularization Diseases (ESGCT 2025) - No abstract available

Gene therapy • Gene Therapies

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Hangzhou Jiayin Biotech Ltd

New P1/2 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

EXG202: A Next Generation AAV-based Gene Therapy for Neovascular AMD Delivered by Intravitreal Injection with Superior Retinal Transduction in NHPs and Remarkable Inhibitory Effect on Retinal Detachment in a Severe Neovascular Mouse Model (ASGCT 2025) - "Efficacy of EXG202 delivered by intravitreal injection was tested in a dose-ranging study in Tet/opsin/VEGF double transgenic mice, with inducible expression of VEGF165 that develop severe vascular leakage and exudative retinal detachment (RD) when treated with doxycycline Adult Tet/opsin/VEGF mice (n =7-9/group) were given an intravitreal injection of EXG202 at doses of 1×107, 3×107, 1×108, 3×108, or 1×109 vg/eye in one eye, and the negative control vector AVT-Luc in the other eye. These data strongly support the clinical development of EXG202 for the treatment of nAMD or DME. Disease Focus of Abstract:Ophthalmic Diseases"

Gene therapy • Preclinical • Gene Therapies • Retinal Disorders • Wet Age-related Macular Degeneration

Efficient Retinal Transduction and Excellent Inhibition on Retinal Detachment of EXG202 in NHP and a Severe Neovascular Leakage Mouse Model (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Preclinical • Age-related Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD) (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Hangzhou Jiayin Biotech Ltd

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration